Claims for Patent: 8,435,760
✉ Email this page to a colleague
Summary for Patent: 8,435,760
Title: | Systems for expression of heterologous proteins in M. capsulatus |
Abstract: | The present invention relates to an expression system for the expression of proteins and peptides in a methanotrophic bacterium, preferably M. capsulatus. Further, the invention relates to the exportation and display of said peptides and proteins on the surface of said bacteria. The invention also describes a method for the production of a desired protein in M. capsulatus. |
Inventor(s): | Lillehaug; Johan R. (Bergen, NO), Jensen; Harald B. (Eidsvag, NO) |
Assignee: | Stiftelsen Universitetsforskning (Bergen, NO) |
Application Number: | 12/677,888 |
Patent Claims: | 1. A recombinant expression vector comprising a promoter, a coding sequence having multiple cloning sites operably linked to and under the control of the promoter, an
intron having the nucleotide sequence set forth as SEQ ID NO. 4 or a nucleotide sequence at least 95% identical to SEQ ID NO. 4 fused with a nucleotide sequence coding for a desired protein or peptide, said intron being operably linked to the coding
sequence.
2. The recombinant expression vector according to claim 1, wherein said protein or peptide is a drug, an antigen or an antibody. 3. The recombinant expression vector according to claim 1, wherein said intron further comprises a gene encoding a selection marker. 4. The recombinant expression vector according to claim 3, wherein said selection marker is an antibiotic selection marker. 5. The recombinant expression vector according to claim 1, wherein said expression vector further comprises a replication origin that functions in the host M. capsulatus. 6. The recombinant expression vector according to claim 5, wherein said replication origin is smmo or pmmo. 7. The recombinant expression vector according to claim 1, wherein the desired protein is expressed in the host M. capsulatus. 8. The recombinant expression vector according to claim 7, wherein the desired protein is expressed on the surface of the outer membrane of M. capsulatus. 9. The recombinant expression vector according to claim 8, wherein the nucleotide sequence coding for the desired protein contains a region which codes for a peptide stretch functioning as a substrate for a hydrolyzing enzyme capable of cleaving the desired protein from the remaining outer membrane anchored protein, such that the desired protein is excreted to the culture medium. 10. The recombinant expression vector according to claim 1, wherein the recombinant vector is a plasmid. 11. The recombinant expression vector according to claim 10, wherein the plasmid is SEQ ID NO. 9 or a sequence least 95% identical to SEQ ID NO. 9. 12. The recombinant expression vector according to claim 1, wherein the intron has a nucleotide sequence chosen from the group consisting of Seq ID NO. 10, SEQ ID NO 12, and SEQ ID No 14, fused with a nucleotide sequence coding for a desired protein or peptide. 13. A bacterial host cell transformed with the recombinant vector according to claim 1. 14. The bacterial host cell according to claim 13, wherein the bacterial cell is M. capsulatus. 15. A method for producing a desired protein in a bacterial host cell, said method comprising transforming a bacterial host cell with a recombinant expression vector comprising a promoter, a coding sequence having multiple cloning sites operably linked to and under the control of the promoter, an intron having the nucleotide sequence set forth as SEQ ID NO. 4 or a nucleotide sequence at least 95% identical to SEQ ID NO. 4 fused with a nucleotide sequence coding for a desired protein or peptide, said intron being operably linked to the coding sequence and culturing said transformed host cell in a suitable medium under conditions allowing expression of said protein. 16. The method according to claim 15, wherein the method further comprises the step of recovering the expressed protein or peptide from the medium. 17. The method according to claim 15, wherein the host cell is M. capsulatus. 18. The method according to claim 15, wherein the desired expressed protein is a drug, wherein said drug is extracted from the host cell, or used together with the host cell for the manufacturing of a vaccine, wherein said vaccine optionally is for oral administration. |
Details for Patent 8,435,760
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2027-09-18 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2027-09-18 | |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2027-09-18 | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.